Active — Not RecruitingNot Applicable

Treatment of Peyronie's Disease With Platelet-Rich Plasma

Denmark10 participantsStarted 2025-03-10

Plain-language summary

The purpose of this pilot study is to optimize a planned randomized, double-blind, placebo-controlled clinical trial evaluating the effects of Platelet-Rich Plasma (PRP) intralesional injections in men affected by Peyronie's disease (PD) in the fibrotic phase. The pilot study aims to identify potential challenges in the practical execution of the clinical trial, particularly regarding PRP preparation and the blinding process. Furthermore, it seeks to evaluate the effects of PRP injections.

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 years or older * Be able to provide written informed consent * Diagnosis of PD without active pain and without progressive curvature over the past 3 months (fibrotic phase). * Penile curvature of 30-95 degrees Exclusion Criteria: * Erectile Dysfunction unresponsive to on-demand PDE5 inhibitors * Hourglass malformation * Severely calcified plaques where injection is considered unfeasible * History of priapism. * History of penile fracture. * Previous treatment for PD with injections and/or surgery.

What they're measuring

Platelet Concentration in the PRP

Timeframe: The 6 week intervention period.

Evaluation of the Blinding Process

Timeframe: The 6 week intervention period.

Trial details

NCT IDNCT06789510

SponsorHerlev Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10-01

View on ClinicalTrials.gov More Peyronies Disease trials